HRP20080544T3 - Benzothiazole formulations and use thereof - Google Patents
Benzothiazole formulations and use thereofInfo
- Publication number
- HRP20080544T3 HRP20080544T3 HR20080544T HRP20080544T HRP20080544T3 HR P20080544 T3 HRP20080544 T3 HR P20080544T3 HR 20080544 T HR20080544 T HR 20080544T HR P20080544 T HRP20080544 T HR P20080544T HR P20080544 T3 HRP20080544 T3 HR P20080544T3
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkoxy
- formula
- well
- benzothiazole
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- -1 C 1 -C 6 -alkoxy Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229960003511 macrogol Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105843 | 2004-11-17 | ||
| US62899804P | 2004-11-18 | 2004-11-18 | |
| PCT/EP2005/056020 WO2006053882A2 (en) | 2004-11-17 | 2005-11-16 | Benzothiazole formulations and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080544T3 true HRP20080544T3 (en) | 2008-12-31 |
Family
ID=36407499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080544T HRP20080544T3 (en) | 2004-11-17 | 2008-10-24 | Benzothiazole formulations and use thereof |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1812072B1 (xx) |
| JP (1) | JP5144271B2 (xx) |
| KR (1) | KR101337726B1 (xx) |
| AR (1) | AR052139A1 (xx) |
| AT (1) | ATE411817T1 (xx) |
| AU (1) | AU2005305880B2 (xx) |
| BR (1) | BRPI0517782A (xx) |
| CA (1) | CA2585316C (xx) |
| CY (1) | CY1108711T1 (xx) |
| DE (1) | DE602005010604D1 (xx) |
| DK (1) | DK1812072T3 (xx) |
| EA (1) | EA011614B1 (xx) |
| ES (1) | ES2315931T3 (xx) |
| HR (1) | HRP20080544T3 (xx) |
| IL (1) | IL182955A (xx) |
| NO (1) | NO20073071L (xx) |
| PL (1) | PL1812072T3 (xx) |
| PT (1) | PT1812072E (xx) |
| SI (1) | SI1812072T1 (xx) |
| WO (1) | WO2006053882A2 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0613042A2 (pt) * | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| EP2298286B8 (en) * | 2009-09-18 | 2017-08-09 | SiTec PharmaBio SL | Process for dewatering of product powders |
| US20120322752A1 (en) * | 2009-12-08 | 2012-12-20 | Sung Kyun Lee | SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL |
| EP2560621A1 (en) * | 2010-04-22 | 2013-02-27 | Ratiopharm GmbH | Fingolimod in the form of a solid solution |
| US20130102683A1 (en) * | 2010-04-22 | 2013-04-25 | Ratiopharm Gmbh | Melt-granulated fingolimod |
| CN113354550B (zh) * | 2021-05-28 | 2023-04-11 | 吉林大学 | 一种氨甲苯酸的制备方法 |
| KR20230164862A (ko) * | 2022-05-26 | 2023-12-05 | 연세대학교 산학협력단 | 아토피피부염의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69811233T2 (de) * | 1997-10-27 | 2003-11-20 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| SE9902742D0 (sv) * | 1999-07-20 | 1999-07-20 | Astra Ab | New pharmaceutical formultion |
| EP1110957A1 (en) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
| ITMI20011338A1 (it) * | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio immediato del principio attivo |
| ITMI20011337A1 (it) * | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio modificato del principio attivo |
| BR0210867A (pt) * | 2001-07-06 | 2004-06-29 | Lifecycle Pharma As | Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio |
| WO2003047570A1 (en) * | 2001-12-07 | 2003-06-12 | Applied Research Systems Ars Holding N.V. | Benzazole derivatives for the treatment of scleroderma |
| WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| IL164796A (en) * | 2002-04-25 | 2013-02-28 | Pascale Gailllard | Piperazine benzothiazole derivatives, their preparation, pharmaceutical compositions containing them and their use |
-
2005
- 2005-11-16 DE DE602005010604T patent/DE602005010604D1/de active Active
- 2005-11-16 AT AT05813663T patent/ATE411817T1/de active
- 2005-11-16 EA EA200701072A patent/EA011614B1/ru not_active IP Right Cessation
- 2005-11-16 SI SI200530523T patent/SI1812072T1/sl unknown
- 2005-11-16 CA CA2585316A patent/CA2585316C/en active Active
- 2005-11-16 WO PCT/EP2005/056020 patent/WO2006053882A2/en active Application Filing
- 2005-11-16 EP EP05813663A patent/EP1812072B1/en active Active
- 2005-11-16 DK DK05813663T patent/DK1812072T3/da active
- 2005-11-16 AR ARP050104822A patent/AR052139A1/es not_active Application Discontinuation
- 2005-11-16 BR BRPI0517782-0A patent/BRPI0517782A/pt not_active IP Right Cessation
- 2005-11-16 PT PT05813663T patent/PT1812072E/pt unknown
- 2005-11-16 ES ES05813663T patent/ES2315931T3/es active Active
- 2005-11-16 JP JP2007541953A patent/JP5144271B2/ja active Active
- 2005-11-16 PL PL05813663T patent/PL1812072T3/pl unknown
- 2005-11-16 KR KR1020077013219A patent/KR101337726B1/ko not_active IP Right Cessation
- 2005-11-16 AU AU2005305880A patent/AU2005305880B2/en active Active
-
2007
- 2007-05-03 IL IL182955A patent/IL182955A/en not_active IP Right Cessation
- 2007-06-15 NO NO20073071A patent/NO20073071L/no not_active Application Discontinuation
-
2008
- 2008-10-24 HR HR20080544T patent/HRP20080544T3/xx unknown
-
2009
- 2009-01-20 CY CY20091100071T patent/CY1108711T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200701072A1 (ru) | 2007-10-26 |
| CA2585316A1 (en) | 2006-05-26 |
| IL182955A0 (en) | 2007-08-19 |
| BRPI0517782A (pt) | 2008-10-21 |
| AR052139A1 (es) | 2007-03-07 |
| IL182955A (en) | 2011-05-31 |
| WO2006053882A2 (en) | 2006-05-26 |
| ATE411817T1 (de) | 2008-11-15 |
| AU2005305880A1 (en) | 2006-05-26 |
| KR101337726B1 (ko) | 2013-12-12 |
| DE602005010604D1 (de) | 2008-12-04 |
| PT1812072E (pt) | 2008-11-04 |
| EA011614B1 (ru) | 2009-04-28 |
| DK1812072T3 (da) | 2008-12-01 |
| WO2006053882A3 (en) | 2006-09-08 |
| ES2315931T3 (es) | 2009-04-01 |
| CY1108711T1 (el) | 2014-04-09 |
| EP1812072A2 (en) | 2007-08-01 |
| KR20070092963A (ko) | 2007-09-14 |
| NO20073071L (no) | 2007-06-15 |
| JP2008520624A (ja) | 2008-06-19 |
| PL1812072T3 (pl) | 2009-04-30 |
| SI1812072T1 (sl) | 2009-04-30 |
| AU2005305880B2 (en) | 2010-08-26 |
| CA2585316C (en) | 2013-06-25 |
| EP1812072B1 (en) | 2008-10-22 |
| JP5144271B2 (ja) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080544T3 (en) | Benzothiazole formulations and use thereof | |
| AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
| NO20014485D0 (no) | Nye forbindelser og sammensetninger som proteaseinhibitorer | |
| MEP52408A (en) | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | |
| CL2004000382A1 (es) | Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6. | |
| EP1248612A4 (en) | NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS | |
| SE0302487D0 (sv) | Novel compounds | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| NO20070445L (no) | Pyrimidinderivater. | |
| MY143400A (en) | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | |
| SE0202463D0 (sv) | Novel compounds | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| HRP20070499A2 (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| DK1263730T3 (da) | Aminderivater til behandling af apoptose | |
| SE0302324D0 (sv) | Novel compounds | |
| PE20020566A1 (es) | DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA | |
| SE0302323D0 (sv) | Novel compounds | |
| AR041299A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| SE0400043D0 (sv) | New compounds | |
| BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| NO20050612L (no) | Pyrrolidinderivater som oksytocinantagonister | |
| EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина | |
| RS20050806A (xx) | 4-supstituisani hinolin derivati,metod i intermedijeri za njihovo dobijanje i farmaceutski oblici koji ih sadrže | |
| ATE444069T1 (de) | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen | |
| ATE469148T1 (de) | Zur behandlung von mit trpv1 in zusammenhang stehenden erkrankungen geeignete 2-(benzimidazol- 1yl)-n-(4-phenylthiazol-2-yl)acetamidderivate |